Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

MRI-Guided Biopsy of Recurrent Prostate Cancer After Radiotherapy

This study is ongoing, but not recruiting participants.
U.S. Army Medical Research and Materiel Command
Princess Margaret Hospital, Canada
Information provided by (Responsible Party):
University Health Network, Toronto Identifier:
First received: October 16, 2008
Last updated: December 28, 2016
Last verified: December 2016
In this study we will test a new procedure to guide needle biopsies into the prostate gland based on MRI. This study will be conducted in patients who may have recurrence of their cancer in the prostate gland after radiation therapy in order to map out the location of the recurrence. Using this technique, we will be able to measure the accuracy of MR images in identifying the site of tumour recurrence.

Condition Intervention
Recurrent Prostate Cancer
Procedure: MRI-Guided Biopsy

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: MRI - Guided Biopsy for Suspicion of Locally Recurrent Prostate Cancer After External Beam Radiotherapy

Resource links provided by NLM:

Further study details as provided by University Health Network, Toronto:

Primary Outcome Measures:
  • The primary endpoint is a preliminary estimate of the diagnostic accuracy of MRI in identifying sites of recurrent tumor after radiotherapy for prostate cancer. [ Time Frame: at the end of the evaluation phase ]

Estimated Enrollment: 90
Study Start Date: October 2006
Estimated Study Completion Date: November 2017
Primary Completion Date: May 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: MRI guided prostate biopsy Procedure: MRI-Guided Biopsy
Technical development and clinical testing of a novel technique for magnetic resonance imaging (MRI) guided prostate biopsy in a 1.5T horizontal bore scanner using a dedicated interventional table.

Detailed Description:
This study involves the technical development and clinical testing of a novel technique for magnetic resonance imaging (MRI) guided prostate biopsy in a 1.5T horizontal bore scanner using a dedicated interventional table. We primarily hypothesize that the integration of diagnostic and interventional MRI enables needle biopsy targeting to foci of tumor recurrence after radiotherapy, and will enable a determination of the diagnostic accuracy of MRI in mapping sub-sites of tumor recurrence after radiotherapy. RELEVANCE TO PUBLIC HEALTH: Patients with recurrence of their prostate cancer after radiotherapy currently face difficult choices. Standard second line treatments target the entire prostate gland and are associated many side effects. This study will directly improve the detection, spatial delineation, and characterization of prostate cancer persistence after radiotherapy. If anatomic patterns of disease persistence are found across patients, radiation delivery techniques will be suitably modified, which may translate to improved cure rates. Importantly, this study will establish a procedural platform for MRI-guidance of minimally invasive local salvage therapies. By precisely focusing salvage therapy to sites of tumor persistence within the prostate gland, side effects may be reduced in the future.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Biochemical failure > 18 months after definitive external beam radiotherapy (ASTRO definition - revised version 2006: rise by 2 ng/mL or more above the nadir PSA)
  • PSA <20 prior to initial course of external beam radiotherapy
  • PSADT >3 months at failure
  • Age ≥ 18 years
  • ECOG performance status 0 or 1 with >10 year life expectancy
  • Fit for local anaesthesia
  • Informed consent:

Exclusion Criteria:

  • Contraindications to MRI
  • Severe claustrophobia
  • Bleeding diathesis and anti-coagulative therapy that cannot be temporarily ceased precluding brachytherapy
  • Previous brachytherapy
  • Active hormonal therapy
  • Radiologic evidence of LN or distant metastases
  • Other urinary or medical conditions deemed by the PI or associates to make the patient ineligible for MRI-guided prostate biopsy.
  • Contraindications to endorectal coil, surgically absent rectum, severe hemorrhoids or previous colorectal surgery
  • Contraindications to conscious sedation
  • Contraindication to IV Gadolinium administration
  • latex allergy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00775866

Canada, Ontario
University Health Network
Toronto, Ontario, Canada, M5G 2M9
Sponsors and Collaborators
University Health Network, Toronto
U.S. Army Medical Research and Materiel Command
Princess Margaret Hospital, Canada
Principal Investigator: Peter Chung, MB ChB University Health Network, Toronto
  More Information

Responsible Party: University Health Network, Toronto Identifier: NCT00775866     History of Changes
Other Study ID Numbers: UHN REB 05-0641-C
Proposal Number PC050204
Award Number W81XWH-05-1-0570
Study First Received: October 16, 2008
Last Updated: December 28, 2016

Keywords provided by University Health Network, Toronto:
prostate cancer, magnetic resonance imaging, guided imagery

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases processed this record on May 24, 2017